All Stories

  1. Health and Health-Related Connected Objects: Regulatory Intersections, Grey Zones and Blind Spots
  2. 8 Exceptions and limitations (27 UPCA)
  3. Governing, Protecting, and Regulating the Future of Genome Editing
  4. Balancing Innovation, ‘Ordre Public’ and Morality in Human Germline Editing: A Call for More Nuanced Approaches in Patent Law
  5. Introduction: The Significance of ELSPI Perspectives in Governing, Protecting, and Regulating the Future of Genome Editing
  6. Balancing Innovation, ‘Ordre Public’ and Morality in Human Germline Editing: A Call for More Nuanced Approaches in Patent Law
  7. Governing, Protecting, and Regulating the Future of Genome Editing: The Significance of ELSPI Perspectives
  8. Sweden: Legal Response to Covid-19
  9. Biobank and Biomedical Research: Responsibilities of Controllers and Processors Under the EU General Data Protection Regulation
  10. Implementation of the Trade Secrets Directive into national law: Portugal and Spain
  11. Rules and Tools in the Battle Against Superbugs—A Call for Integrated Strategies and Enhanced International Collaboration to Promote Antimicrobial Drug Development
  12. Regulating germline editing in assisted reproductive technology: An EU cross‐disciplinary perspective
  13. Legal method and interpretation in international IP law: pluralism or systemic coherence
  14. Large expert-curated database for benchmarking document
  15. Patentability of human enhancement: from ethical dilemmas to legal (un)certainty
  16. Cutting edges and weaving threads in the gene editing (Я)evolution: reconciling scientific progress with legal, ethical, and social concerns
  17. A “Ray of Hope” for European Stem Cell Patents or “Out of the Smog into the Fog”? An Analysis of Recent European Case Law and How it Compares to the US
  18. The Impact of “Broccoli II” and “Tomatoes II” on European Patents in Conventional Breeding, GMOs, and Synthetic Biology: The Grand Finale of a Juicy Patents Tale?
  19. Patentability of methods of human enhancement